acetyl- sarcosyl- glycyl- valyl- isoleucyl- threonyl- norvalyl- isoleucyl- arginyl- proline ethylamide

12/15/2006 - "A modified nonapeptide from TSP-I, ABT-526, has been found to be active in mouse cancer models and in dogs with naturally occurring cancers. "
12/15/2006 - "A prospective open-label trial using ABT-510 or ABT-526 in pet dogs with measurable malignant spontaneously arising tumors. "
12/15/2006 - "These results support the safety and activity of ABT-526 and ABT-510 in dogs with naturally occurring malignant cancers. "
12/15/2006 - "ABT-526 and ABT-510, two peptide mimetics of thrombospondin-1 (TSP-1), block angiogenesis in vitro and in vivo and slow tumor growth in mice. "
12/15/2006 - "Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers."

12/15/2006 - "To further assist in the development of ABT-526, we report herein on its evaluation in combination with cytotoxic chemotherapy in pet dogs with relapsed non-Hodgkin's lymphoma (NHL). "

12/15/2006 - "Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma."